- Home
- TNON vs ONVO Comparison
TNON vs ONVO Comparison
Compare TNON & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNON
- ONVO
- Stock Information
- Founded
- TNON 2012
- ONVO 2007
- Country
- TNON United States
- ONVO United States
- Employees
- TNON N/A
- ONVO N/A
- Industry
- TNON Medical Specialities
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TNON Health Care
- ONVO Health Care
- Exchange
- TNON Nasdaq
- ONVO Nasdaq
- Market Cap
- TNON 3.2M
- ONVO 3.0M
- IPO Year
- TNON 2022
- ONVO N/A
- Fundamental
- Price
- TNON $1.17
- ONVO $1.87
- Analyst Decision
- TNON Strong Buy
- ONVO
- Analyst Count
- TNON 3
- ONVO 0
- Target Price
- TNON $11.67
- ONVO N/A
- AVG Volume (30 Days)
- TNON 1.1M
- ONVO 347.1K
- Earning Date
- TNON 05-13-2025
- ONVO 05-30-2025
- Dividend Yield
- TNON N/A
- ONVO N/A
- EPS Growth
- TNON N/A
- ONVO N/A
- EPS
- TNON N/A
- ONVO N/A
- Revenue
- TNON $3,277,000.00
- ONVO $122,000.00
- Revenue This Year
- TNON $118.16
- ONVO $59.08
- Revenue Next Year
- TNON $14.25
- ONVO $18.24
- P/E Ratio
- TNON N/A
- ONVO N/A
- Revenue Growth
- TNON 11.92
- ONVO N/A
- 52 Week Low
- TNON $0.91
- ONVO $1.56
- 52 Week High
- TNON $15.79
- ONVO $21.96
- Technical
- Relative Strength Index (RSI)
- TNON 46.02
- ONVO 37.84
- Support Level
- TNON $1.06
- ONVO $1.56
- Resistance Level
- TNON $1.19
- ONVO $1.78
- Average True Range (ATR)
- TNON 0.11
- ONVO 0.24
- MACD
- TNON -0.01
- ONVO 0.13
- Stochastic Oscillator
- TNON 51.67
- ONVO 43.06
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants, and 3) SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.